Premium
Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat
Author(s) -
Finberg J.P.M.,
Youdim Moussa B.H.
Publication year - 1985
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1985.tb08891.x
Subject(s) - clorgyline , selegiline , nictitating membrane , tyramine , monoamine oxidase , monoamine oxidase b , chemistry , pharmacology , monoamine oxidase a , endocrinology , medicine , parkinson's disease , biochemistry , enzyme , classical conditioning , statistics , mathematics , disease , conditioning
1 The selective monoamine oxidase (MAO) inhibitors clorgyline, selegiline and AGN 1135 did not cause a change in responses of the cat nictitating membrane to preganglionic sympathetic nerve stimulation at 5 Hz. 2 Both selective MAO‐A and MAO‐B inhibitors markedly potentiated nictitating membrane contractions in response to β‐phenylethylamine (PEA). However, the responses to tyramine were unchanged. 3 The pressor responses to tyramine were potentiated by the selective MAO‐A inhibitor clorgyline (2 mg kg −1 ) but not by selegiline (1.0 mg kg −1 ) and AGN 1135 (1.5 mg kg −1 ), selective MAO‐B inhibitors. 4 At the doses used selegiline and AGN 1135 caused a near total selective inhibition of liver and brain MAO‐B, while clorgyline inhibited MAO‐A only in the brain. 5 AGN 1135, like selegiline, could be a useful drug in potentiating the action of L‐DOPA in Parkinson's disease.